Company intelligence / Profile preview

Advamedica

Cambridge, Massachusetts, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Advamedica is a MedTech company developing biomaterial-based medical devices for hemostasis and wound care, utilizing its Protonated Bioadhesive Technology (Chitosan-based biopolymer platform). Key products include Axiostat and Ax-Surgi (FDA 510(k) cleared as the first chitosan-based hemostat for severe surgical bleeding). MaxioCel is a commercial product with Phase IV clinical data demonstrating superior wound healing and exudate management.

Therapeutic areas: CardiovascularHematologyOtherDermatology
Modalities: DeviceBiologic
Industry: Therapeutic Medical Devices

Partnerships

Brigham and Women's Hospital at Harvard Medical School (academic collaboration)

Beyond the preview

Go deeper on Advamedica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Advamedica.

Explore the full profile